Pathstone Family Office’s Bioverativ Inc. Common Stock BIVV Stock Holding History

Pathstone Family Office’s Portfolio BIVV Stock Details BIVV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-83	Closed	-$4K	–	390
2017 Q4	$4K	Buy	+83	New	+$4.54K	﹤0.01%	115
2017 Q3	–	Sell	-83	Closed	-$5K	–	380
2017 Q2	$5K	Sell	83 -2	-2%	-$114	﹤0.01%	341
2017 Q1	$5K	Buy	+85	New	+$4.19K	﹤0.01%	324

Other funds holding BIVV

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

ACS

Archford Capital Strategies Swansea, Illinois $987M AUM 29.31% 1-Year Est. Return

Pathstone Family Office's BIVV Position: Q1 2018 in Review

Pathstone Family Office sold out of Bioverativ Inc. Common Stock (BIVV) in Q1 2018, closing a stake of 83 shares — an estimated $4K sold.

Pathstone Family Office first reported a position in BIVV in Q1 2017 and held it in 3 quarters. The position peaked at $5K in Q2 2017. 2 funds tracked by Wall St. Rank hold BIVV as of Q1 2018.

Pathstone Family Office reported no remaining Bioverativ Inc. Common Stock position as of Q1 2018 after selling out during the quarter.
Pathstone Family Office sold 83 Bioverativ Inc. Common Stock shares in Q1 2018, an estimated $4K.
Pathstone Family Office first reported a position in Bioverativ Inc. Common Stock in Q1 2017 and held it in 3 quarters.
Pathstone Family Office's Bioverativ Inc. Common Stock position peaked at $5K in Q2 2017.
2 funds tracked by Wall St. Rank held Bioverativ Inc. Common Stock as of Q1 2018.

Based on Pathstone Family Office's 13F filing for Q1 2018, filed 15 May 2018.